Literature DB >> 25694251

[Do new oral therapies show advantages in the basal therapy of multiple sclerosis? Pro].

S G Meuth1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25694251     DOI： 10.1007/s00115-014-4243-z

Source DB:  PubMed          Journal:  Nervenarzt        ISSN： 0028-2804            Impact factor:   1.214


× No keyword cloud information.
  3 in total

1.  The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis.

Authors:  V Devonshire; Y Lapierre; R Macdonell; C Ramo-Tello; F Patti; P Fontoura; L Suchet; R Hyde; I Balla; E M Frohman; B C Kieseier
Journal:  Eur J Neurol       Date:  2011-01       Impact factor: 6.089

2.  Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

Authors:  Paul O'Connor; Jerry S Wolinsky; Christian Confavreux; Giancarlo Comi; Ludwig Kappos; Tomas P Olsson; Hadj Benzerdjeb; Philippe Truffinet; Lin Wang; Aaron Miller; Mark S Freedman
Journal:  N Engl J Med       Date:  2011-10-06       Impact factor: 91.245

3.  Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM. Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107; and Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97.

Authors:  Eva Havrdova; Michael Hutchinson; Nuwan C Kurukulasuriya; Kartik Raghupathi; Marianne T Sweetser; Katherine T Dawson; Ralf Gold
Journal:  Expert Opin Pharmacother       Date:  2013-08-24       Impact factor: 3.889
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.